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We report 15 individuals with de novo pathogenic variants in WDR26. Eleven of the individuals carry loss-of-function mutations, and
four harbor missense substitutions. These 15 individuals comprise ten females and five males, and all have intellectual disability with
delayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, spastic, and/or stiff-legged gait. These subjects share
a set of common facial features that include a prominentmaxilla and upper lip that readily reveal the upper gingiva, widely spaced teeth,
and a broad nasal tip. Together, these features comprise a recognizable facial phenotype. We compared these features with those of chro-
mosome 1q41q42 microdeletion syndrome, which typically contains WDR26, and noted that clinical features are consistent between
the two subsets, suggesting that haploinsufficiency of WDR26 contributes to the pathology of 1q41q42 microdeletion syndrome.
Consistent with this,WDR26 loss-of-function single-nucleotide mutations identified in these subjects lead to nonsense-mediated decay
with subsequent reduction of RNA expression and protein levels. We derived a structural model of WDR26 and note that missense var-
iants identified in these individuals localize to highly conserved residues of this WD-40-repeat-containing protein. Given thatWDR26
mutations have been identified in 1 in 2,000 of subjects in our clinical cohorts and thatWDR26might be poorly annotated in exome
variant-interpretation pipelines, we would anticipate that this disorder could be more common than currently appreciated.Characterizing and identifying syndromic forms of intel-
lectual disability can be difficult for both clinicians and sci-
entists. This is typically due to variability in the severity,
associated features, and rarity of these disorders. Several
of these challenges have improved with the advent of
genome-wide sequencing coupled with careful standard-
ized phenotyping and highly collaborative networks,
which have markedly facilitated the identification, charac-
terization, and recognition of rare syndromic disorders
with intellectual disability. However, limitations often
related to poor annotation or understanding of gene
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 2017related genes. Here, we report the recognition of a role
for WDR26 (WD40 repeat protein 26 [MIM: 617424]) in
human syndromic intellectual disability. This recognition
was dependent upon the presence of de novo variants,
the utilization of broad reference datasets that included
this variably annotated gene, and a concerted effort of in-
ternational collaborators to identify individuals and char-
acterize the clinical features.
In the evaluation of two individuals (1 and 2) with
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Table 1. Pathogenic WDR26 Variants
Individual
cDNA Notation
(GenBank:
NM_025160.6)
Predicted Effect
on Protein
(GenBank:
NP_079436.4) Inheritance
1 c.1276G>T p.Glu426* de novo
2 c.1161_1162del p.His389Profs*6 de novo
3 c.1457del p.Val486Glufs*9 de novo
4 c.644T>C p.Leu215Pro de novo
5 c.904_905del p.Gln302Aspfs*22 de novo
6 c.850G>A p.Asp284Asn de novo
7 c.137C>A p.Ser46* de novo
8 c.1570C>T p.Gln524* de novo
9 c.762T>G p.Ser254Arg de novo
10 c.1284G>A p.Trp428* de novo
11 c.1419þ2dupT splice site de novo
12 c.835C>T p.Arg279* de novo
13 c.574dupA p.Ile192Asnfs*8 de novo
14 c.514T>A p.Trp172Arg de novo
15 c.1149_1158þ1del p.Val384fs de novoeach was noted to have a de novo nonsense mutation in
the minimally characterized gene WDR26. Although this
gene was not included in the OMIM gene set until recently
(added March 31, 2017), it is included in Agilent v.4 and
later exome capture sets (Agilent) as part of the RefSeq
gene set.1 The probability of loss-of-function intolerance
(pLI)2 for WDR26 in the Exome Aggregation Consortium
(ExAC) Browser was 1.00, strongly supporting that
these variants are pathogenic. Subsequently, WDR26 was
included in lab gene annotation datasets that enabled
the identification of additional de novo loss-of-function
and missense variants (ExAC missense Z score for 68
observed and 175 expected: Z ¼ 3.942). Identification of
additional subjects withWDR26 variants was subsequently
facilitated by the use of GeneMatcher,3 PhenomeCentral,4
and DECIPHER5 as part of the Matchmaker Exchange Re-
positories.6 We consequently identified 15 subjects with
pathogenic variants of WDR26. All mutations were de
novo, identified via trio exome sequencing, and included
five frameshift, five nonsense, one splice site, and four
missense mutations (Table 1). Individuals were identified
in cohorts of 28,700 exomes for all indications and in
21,400 exomes for individuals with intellectual disability,
giving a frequency of 1 in 2,000 for all exome analyses
and 1 in 1,500 for individuals with intellectual disability.
To compare and characterize the clinical features of these
individuals, we obtained consent and collected clinical in-
formation. Consent for publication was obtained for all
photographs included in this manuscript. All individuals
for whom evaluation or analysis beyond routine clinical
care was performed were enrolled in a protocol with140 The American Journal of Human Genetics 101, 139–148, July 6, 2informed consent approved by the institutional review
board of the Children’s Hospital of Philadelphia, the Com-
missie Mensgebonden Onderzoek Regio Arnhem-Nijme-
gen, the Rouen University Hospital, the Health and
Disability Ethics Committee of New Zealand, the East of
England – Cambridge South of the National Research
Ethics Service for the Deciphering Developmental Disor-
ders (DDD) UK study, or the UK research ethics committee
(REC) (10/H0305/83 granted by the Cambridge South REC
and GEN/284/12 granted by the Republic of Ireland REC).
A clinical case report for each subject is included in the
Supplemental Note. Detailed molecular and clinical fea-
tures for each individual have been compiled in Table S1.
The 15 subjects (10 females and 5 males) range in age
from 24 months to 34 years. Consistent phenotypic fea-
tures of these individuals include variable developmental
delay, seizures, and similar facial features (Tables 2 and
S1). Developmental delay ranges from mild to severe,
and all individuals have delayed speech; four individuals
had absent speech at the time of assessment (two at 4 years,
one at 5.5 years, and one at 8 years). Individual 2, the
oldest individual in the cohort, is described as having dys-
arthric speech as an adult. Motor delay is also common,
such that the emergence of walking was reported from
17 months to 3 years. Of the ten individuals with available
descriptions, all were described as having a wide-based,
spastic, hemiparetic, and/or stiff-legged gait. Several sub-
jects have stereotypies, including rocking behavior and
abnormal handmovements or posturing, and overall, indi-
viduals are described as happy and socially engaging.
Neurologic abnormalities are also common among the
subjects. All individuals have a history of seizures,
including febrile and/or non-febrile seizures, and several
required antiepileptic medications for a period of time.
The reported non-febrile seizure types include tonic-
clonic, absence, and Rolandic, and age of onset ranges
from the newborn period to 7 years. Minor structural brain
malformations are present in 9 of 13 individuals. One fe-
male (individual 14) had a markedly abnormal left supra-
tentorial hemispheric structure and has now had a left
hemispherectomy with resulting hemiparesis. Hypotonia,
often noted to bemild, was described in 9 of 12 individuals
for whom information was available.
Individuals with mutations inWDR26 also share a set of
identifiable facial features (Figures 1 and S1). Common fea-
tures include a prominent maxilla and upper lip (13/15),
wide mouth (10/15), abnormal gingiva (9/15), widely
spaced teeth (13/15), mildly coarse facial features (12/15),
and a broad or full nasal tip (11/15). The gingival display
represents a relatively unique finding (see individual 10
in Figure 1), but with the current relatively small number
of individuals, it’s unclear whether this represents
increased vertical height of the maxilla or an inferiorly dis-
placed attachment of the maxillary gingiva. This feature is
an isolated finding in 7/15 individuals and manifests with
overt gingival hyperplasia in an additional two individ-
uals. Other facial features include anteversion of the nares017
Table 2. Common Facial Features of Individuals with WDR26 Mutations and 1q41 Microdeletions
Features WDR26 (n ¼ 15) 1q41q42 Microdeletions IncludingWDR26 (n ¼ 17)
Developmental delay or intellectual disability 15/15 15/15
Seizures 15/15 13/14
CNS structural anomalies 10/14 11/15
Hypotonia 9/12 5/15
Abnormal gait 9/9 1/15
Happy and/or friendly personality 10/11 2/2
Autistic and/or repetitive behaviors or posturing 5/9 1/1
Coarse facial features 12/15 12/16
Full cheeks as a child 11/13 7/8
Abnormal eyebrows 6/15 5/12
Depressed nasal root 5/15 11/15
Anteverted nares 8/15 9/13
Full nasal tip 11/15 9/14
Prominent maxilla and protruding upper lip 13/15 7/12
Decreased cupid’s bow 11/15 10/12
Widely spaced teeth 13/15 7/8
Abnormal gums 9/15 6/6
Fractions indicate the number observed over the number reported or ascertained. The following abbreviation is used: CNS, central nervous system.(8/15), a tendency toward full cheeks in childhood (11/13),
sparse lateral eyebrows (6/15), subjectively large irises
often with rounded palpebral fissures (10/15), a depressed
nasal bridge (5/15), mild micrognathia (5/15), and a
partially flattened or decreased Cupid’s bow of the upper
vermillion border (11/15). Ophthalmologic abnormalities
include strabismus and/or amblyopia (9/14) and Marcus
Gunn jaw winking (1/15). Two individuals have small
structural cardiac defects (one with a right sided aortic
arch and one with a ventricular septal defect). One individ-
ual (individual 10) has a cleft palate. No subjects have ma-
jor structural defects of the respiratory or gastrointestinal
systems. Six individuals have been described as having
feeding difficulties and/or failure to thrive. Although skel-
etal findings were ascertained in only a minority of sub-
jects, one (individual 8) was found to have osteopathia
striata of the distal femurs, two have pes cavus (individuals
9 and 11), one has moderate forefoot varus and mild left
hip dysplasia (individual 13), and two have mild contrac-
tures of the lower extremities (knees in individual 8 and
knees and hips in individual 10).
WDR26 is located in chromosomal region 1q42, which is
proposed to be implicated in 1q41q42 microdeletion syn-
drome.7 The findings of individuals with 1q42 deletions
are characterized by consistent facial features, develop-
mental delay, and a predisposition for seizures. Other
clinical features in some individuals include short stature,
microcephaly, andmultiple structural anomalies including
cleft palate, clubfoot, congenital heart disease, and
congenital diaphragmatic hernia.7–14 Deletions for theseThe Amsubjects range in size from 300 kb to 10 Mb and include
varied subsets of genes. However, somewhat strikingly, a
comparison of the clinical and facial features of subjects
with minimal microdeletions, as noted in additional
photos of individual 16 (Figure 1) from Au et al.15 and
the subject reported in Cassina et al.,16 and of subjects
with isolated WDR26 mutations demonstrates a nearly
complete overlap.
This overlap between clinical features of individuals
with WDR26 variants and those seen with 1q4142 micro-
deletions suggests that both result from haploinsufficiency
of WDR26. However, it is formally possible that the
missense, nonsense, and frameshift variants identified
could lead to a dominant-negative protein. Furthermore,
very little is known about the regulation of WDR26
mRNA, which raises the possibility thatWDR26 nonsense
or truncating mutations could occur in a stable mRNA and
lead to the formation of a truncated, dominant-negative
protein. To rigorously test these possibilities, we performed
several experiments. First, because nonsense and frame-
shift mutations often lead to nonsense-mediated decay of
mutant mRNA,17,18 we tested the stability of mutant
mRNA in each of three available lymphoblastoid cell lines
derived from subjects with de novo WDR26 mutations
(individuals 2, 5, and 6), along with two control samples.
In comparison to the equal presence of mutant and
wild-type alleles in genomic DNA (Figure 2A, top
row), the mutant allele was markedly reduced in cDNA
derived from untreated cell lines with frameshift muta-
tions (Figure 2A, middle row, two left panels). Becauseerican Journal of Human Genetics 101, 139–148, July 6, 2017 141
Figure 1. Clinical Features of Individuals with Pathogenic WDR26 Variants
Each individual is noted with a number that corresponds to that used throughout the manuscript. Images are clustered for each
individual. Included on the top left of each cluster is the variant identified, the sex, and an additional study identifier, also noted in
Table S1 at the right.cycloheximide (CHX) is an inhibitor of nonsense-medi-
ated decay of mRNA, we also treated the cell lines with
cycloheximide before production of cDNA.With this treat-
ment, we observed stabilization of the mutant mRNA
allele (Figure 2A, bottom row, two left panels), consistent
with nonsense-mediated decay in cycloheximide-un-
treated cells. We also observed no truncated WDR26 in
any of the cell lines with western blotting (data not
shown). We noted that, in contrast to the frameshift al-
leles, the missense mutation (c.850G>A, predicted to142 The American Journal of Human Genetics 101, 139–148, July 6, 2encode p.Asp284Asn) did not exhibit loss of expression
of the mutant allele in the absence of cycloheximide,
consistent with the expected absence of nonsense-medi-
ated decay and suggesting an alternative mechanism of
pathogenicity. Second, to assess whether this nonsense-
mediated decay leads to a reduction in WDR26 mRNA,
as would be expected for haploinsufficiency, we per-
formed quantitative RT-PCR of total WDR26 mRNA levels
from these same cell lines. These data demonstrated signif-
icant reductions for the frameshift mutations but only a017
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Figure 2. Effect of WDR26 Mutations on Nonsense-Mediated
RNA Decay and Protein Levels
(A)Nonsense-mediatedmRNAdecay (NMD)analysis. Epstein-Barr-
virus-immortalized lymphoblastoid cell lines (LCLs) from subject 2
(c.1161_1162del [p.His389Profs*6], labeled p.H389fs), subject 4
(c.644T>C [p.Gln302Aspfs*22], labeled p.Q302fs), and subject 6
(c.850G>A [p.Asp284Asn], labeled p.D284N) were cultured in the
presence of 1 mg/mL cycloheximide (CHX) for 6 hr and analyzed
by RT-PCR and sequencing for the presence of wild-type and
mutant alleles. Sequencing chromatograms for heterozygous
genomicDNA as reference, untreated, andCHX-treated conditions
are shown, demonstrating the reduced presence of the frameshift
alleles but not the missense allele, denoted by an arrow at the
location of the mutation and summarized result of the NMD assay
(þ or ).
(B) WDR26 RNA expression levels. Consistent with (A), digital
droplet-based quantitative RT-PCR of WDR26 mRNA expression
normalized to TBP mRNA demonstrated a statistically significant
reduction of expression for the frameshift alleles (69% for
c.1161_1162del and 73% for c.644T>C) but not for the
c.850G>A missense allele (88%).
(C) WDR26 levels were quantified by fluorescent western blotting
and normalized to tubulin. Significantly lowerWDR26 levels than
control levels were noted for each pathogenic allele tested (75%
for p.His389Profs*6, 70% for p.Gln302Aspfs*22, and 85% for
p.Asp284Asn). Themean and SEM, alongwith unpaired two-tailed
The Amnon-significant trend for the c.850G>Amissensemutation
(Figure 2B), suggesting a possible alternative pathogenic
mechanism for missense variants. Lastly, to assess the
effect of these variants on total protein levels, we per-
formed quantitative western blotting with normalization
to tubulin (Figure 2C). This demonstrated strongly signifi-
cant reductions in WDR26 levels for the frameshift alleles
and amild reduction for the p.Asp284Asnmissense variant
(Figure 2C). Together, these data confirm that clinical fea-
tures most likely arise from WDR26 haploinsufficiency
and suggest that WDR26 missense variants could alter pro-
tein stability and also lead to reduced function in amanner
consistent with deletion and loss-of-function alleles.
To further explore the mechanism of pathogenicity
for the de novo WDR26 missense variants, we assessed
their conservation and localization within the protein.
WDR26, typical for this protein class, contains WD-40 re-
peats (Figure 3A) and conserved LisH (LIS1 homology)
and CTLH (C-terminal LIS homology) domains.19,20 Each
of the de novo missense WDR26 variants is located within
a region of high sequence phylogenetic conservation
(Figure 3B) and in one of these key motifs. Residues
Trp172 and Leu215 are identical phylogenetically through
Drosophila, whereas more notably, both Ser254 and Asp284
are identically conserved through yeast. This suggests
that even subtle changes at these sites would be poorly
tolerated. Consistent with this, the ExAC Residual Vari-
ance Intolerance Score (ExAC RVIS) for WDR26 is
18.1%,21 and the subRVIS for the domains containing
amino acids 172, 215, 254, and 284 is 9.2% (guidelines
state that less than 35% is not tolerated22). Also consis-
tently, the residue-specific prediction algorithms SIFT,
PROVEAN, PolyPhen-2, and MutationTaster all predict
the p.Trp172Arg, p.Leu215Pro, and p.Ser254Arg variants
to be damaging. Finally, although there are mixed results
for the informatics assessment of p.Asp284Asn, which al-
ters the charge for a residue identically conserved through
yeast, it is predicted to be damaging by PROVEAN and
MutationTaster.
To better understand the potential effect of the missense
variants identified in these subjects, we modeled a struc-
ture for WDR26 on the solved crystal structure for
Drosophila WDS (PDB: 4CY3),23 a homolog of human
WDR5 in humans and a closely related WDR protein. In
contrast with previous primary-sequence-based domain
calling approaches, which suggest that WDR26 contains
five, six, or seven WD-40 repeats,19,20,24–26 our model
for WDR26 suggests that it contains 14 variably perfect
WD-40 repeats, each of which forms four-stranded
anti-parallel b sheets or blades, and together they all
compose two seven-bladed complete b propeller structures
(Figures 3A and 3C). WD-40 domains 1–7 (WD1–WD7,
amino acids 1–353) comprise an N-terminal b propeller,p values comparing multiple biological replicates (three for RNA
and seven for protein) with controls, are demonstrated for each
condition.
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Figure 3. Localization of WDR26 Variants
(A) Schematic domains of WDR26. Illustrated are the key domains of WDR26, which include the 14 deduced WD repeats (larger dark-
gray boxes labeledWD1–WD14; insertions in the domains are noted by unfilled gray bordered segments), the LisH and CTLH homology
domains (in aqua and purple, respectively), and the location of loss-of-function (orange stars) and missense (red circles) variants. Scale
numbers demonstrating amino acid residues are indicated beneath.
(B) Localization of WDR26 missense variants to highly conserved residues in WD repeats near the CTLH domain. ClustalW homology
alignments for human WDR26a (UniProtKB: Q9H7D7; GenBank: NP_079436.4), Chimpanzee (Pan troglodytes) WDR26 (UniProtKB:
K7CSM5), mouse (Mus musculus) WDR26 (UniProtKB/Swiss-Prot: Q8C6G8.3), frog (Xenopus laevis) WDR26 (UniProtKB: A0A0H5BJW1),
zebrafish (Danio rerio) WDR26a (GenBank: NP_001189371.1) and predicted WDR26b (GenBank: XP_001921656.4), fruit fly (Drosophila
melanogaster) WDR26 (UniProtKB/Swiss-Prot: Q7K0L4.1), and yeast (Saccharomyces cerevisiae S288c) GID7 (UniProtKB/Swiss-Prot:
P25569.2) are shown. Identical residues are in dark gray with a black outlined border. Similar residues are indicated with light-gray
shading and no border. Mutated residues are noted above, and red boxes denote the position in all species. Gray and purple boxes
beneath denote the WD and CTLH domain boundaries, respectively.
(C) Structural model ofWDR26 with variants. Illustrated are structural models ofWDR26 with a direct view of the N-terminal b propeller
domain (left) and an 80 rotation toward the viewer to directly show the C-terminal b propeller domain (right). b sheets are illustrated
as flat directional arrows. Note the organization of four b sheets into WDmodules. The LisH and CTLH domains are noted by aqua and
purple shading, respectively, of the protein backbone. Locations of variants are labeled and indicated; missense mutations are indicated
by red shading of the residue and sidechain, and the relative position of loss-of-function alleles is noted by orange shading of the protein
backbone.and WD8–WD14 (amino acids 354–645) comprise a C-ter-
minal b propeller. The C-terminal b propeller is 80 off-
axis from the N-terminal b propeller and contains the
conserved LisH and CTLH domains (Figure 3C shows two
views to illustrate each b propeller). Consistent with
key functional roles, p.Trp172Arg (individual 14) and
p.Leu215Pro (individual 4) lie within the CTLH domain,
and p.Leu215Pro lies in the WD5 repeat in a key b sheet
residue. Similarly, p.Ser254Arg (individual 9) lies in the
neighboring WD6 repeat at the edge of a b sheet. The
locations of these variants suggest that alterations in
b sheets, which comprise essential components of the
WD repeats, result in peptides with abnormal function144 The American Journal of Human Genetics 101, 139–148, July 6, 2and/or instability of the b propeller motif. In comparison,
p.Asp284Asn (individual 6) lies within a predicted loop
that is less well structured and extends from the surface
of the protein to lie outside of the b propeller structure.
In combination with the localization of this variant, the
very high conservation of this region (Figure 3B), along
with data suggesting that functional specificity of WD-40
proteins is determined by domains that extend from the
b propeller,27 suggests that the Asp284 residue could be
involved in key extrinsic interactions. This also suggests
that protein stability might be more tolerant of alteration
at this site, a finding noted above by western blotting
of WDR26 from the lymphoblastoid cells from this017
Table 3. Growth Parameters for Individuals with WDR26 Mutations
Parameter n Average (Z Score) Range (Z Score) No. Abnormal (No. < Z Score)
Birth weight 13 0.9 2.0 to 1.8 4/13 % 1.5
Later Time Point
Length 15 0.6 4.0 to 1.4 2/15 % 1.5
Weight 14 0.9 5.0 to 4.3 6/14 % 1.5
OFC 14 0.9 3.0 to 1.1 3/14 % 1.5
Fractions indicate the number observed over the number reported or ascertained. The following abbreviation is used: OFC, occipital-frontal circumference.individual (Figure 2C). The finding of similar clinical fea-
tures of individuals with 1q41q42 microdeletions, loss-
of-function nonsense and frameshift mutations, and
missense mutations suggests that the missense variants
identified in these individuals disrupt a key function of
WDR26.
In total, we have identified 15 subjects with mutations
that result in haploinsufficiency of WDR26. Because of
the location of WDR26 within the 1q41q42 deletion syn-
drome region, it might have been considered a candidate
gene for causing the similar clinical features noted in these
individuals. Of note, these microdeletions range in size
from 300 kb to 10Mb and include a varied subsets of genes;
in fact, several attempts have been made to identify po-
tential candidate genes for the clinical features seen
in these individuals.7–16 More recently, two papers15,16
described individuals with intellectual disability, seizures,
and dysmorphic features with 590 and 286 kb deletions
on 1q41q42 that included FBXO28 (MIM: 609100) and
WDR26, along with DEGS1 (MIM: 615843), NVL (MIM:
602426), MIR320B2, CNIH4 (MIM: 617483), MIR4742,
and CNIH3 (Figure S2). Each concluded that, along with
previously published cases, this narrowed the region of
overlap to include a single candidate gene, FBXO28. How-
ever, these and previous analyses relied on the observation
by Shaffer et al.7 thatWDR26was excluded from the small-
est region of overlap by a single individual (subject 5).
When reviewing this case in light of our current recogni-
tion of a facial phenotype associated with isolated
WDR26 mutations (Figures 1 and S1 and Tables 2, 3, and
S1), we found that this individual lacks the characteristic
facial features. Given that he has a large (5.1 Mb) deletion,
it is likely that his associated features are due to haploinsuf-
ficiency of other genes. Furthermore, the ExAC pLI of 1.0
and constraint for missense variants of Z ¼ 3.94 for
WDR26 are consistent with a very strong effect if deleted,
whereas the pLI for FBXO28 is less significant at 0.93,
and all other genes in this interval demonstrate pLIs less
than these. Together, when assessing both neurocognitive
and facial phenotypes, these genetic data support that
WDR26 is the likely candidate gene whose haploinsuffi-
ciency is the cause of 1q41q42 deletion syndrome.
Assessment of the mechanism by which WDR26 hap-
loinsufficiency leads to human developmental disorders
has yet to be elucidated. WDR26 is expressed in most hu-The Amman tissues, including the brain and skeletal muscle
at both fetal and adult stages,19 consistent with the
tissues involved in individuals with WDR26 mutations.
However, multiple roles have been proposed for WDR26.
Data from relatively few studies suggest that it could
play wide-ranging roles in regulation of MAPK, Wnt,
and PI3K signaling; neuronal and cardiomyoblast prolifer-
ation; apoptosis signaling; and leukocyte activation and
signaling.19,20,24–26,28–30 We have tested cell lines derived
from heterozygous subjects for evidence of altered Wnt
signaling but have not noted any changes in lymphoblas-
toid or fibroblast cell types (data not shown).
Similarly, additional understanding of the biological
function of WDR26 could indeed benefit from insight
gained from clinical features of individuals with WDR26
mutations. For example, the observed common fea-
tures (including intellectual disability more prevalently
involving speech; seizures; wide-based, spastic, and/or
stiff-legged gait; a prominent maxilla and upper lip; and
widely spaced teeth; Tables 2 and S1) could underlie the
reasons that several alternative diagnoses were considered
for individuals in this cohort. Considered diagnoses
included Angelman syndrome (MIM: 105830; individuals
4, 7, 10, and 11) and Pitt-Hopkins syndrome (MIM:
610954; individual 4), suggesting a disorder of neuronal
development.31 In addition, atypical Cornelia de Lange
syndrome (MIM: 122470; individuals 1 and 6), Coffin-
Siris syndrome (MIM: 135900; individual 1), Floating-
Harbor syndrome (MIM: 136140; individual 6), X-linked
alpha-thalassemia/mental retardation syndrome (MIM:
301040; individuals 7, 9, and 15), Kabuki syndrome
(MIM: 147920; individual 13), and Kleefstra syndrome
(MIM: 610253; individuals 12 and 15) were considered.
These diagnoses suggest that additional possible patho-
genic mechanisms for WDR26 haploinsufficiency might
be related to chromatin regulation.32–37 This would be
consistent with an overlap between the clinical features
in these subjects and those of the recently denoted
‘‘transcriptomopathies.’’38,39
In summary, we coupled exome sequencing with variant
annotation and interpretation via pipelines including
broadly annotated gene sets, alongwith global collaborative
tools, to identify human mutations inWDR26. This cohort
of individuals demonstrates a recognizable phenotype
of intellectual disability, developmental delay, seizures,erican Journal of Human Genetics 101, 139–148, July 6, 2017 145
abnormal gait, and characteristic facial features that include
a prominent maxilla and upper lip that readily reveal the
upper gingiva and widely spaced teeth. Notably, this gene,
although included in most exome capture sets, it is not
included in some database gene analysis sets. We would
suggest that if aWDR26mutation is suspected in an indivi-
dual on the basis of clinical features, previous exome data
could be reanalyzed.Given the phenotypic andmechanistic
overlap of haploinsufficiency, WDR26 is most likely the
major contributory gene in 1q41q42 deletion syndrome as
a major factor in the neurocognitive and facial phenotypes.
Finally, although little is known to date about its function,
we anticipate that reduced expression of WDR26 alters
multiple signaling pathways and cellular mechanisms to
result in this recognizable human phenotype.Supplemental Data
Supplemental Data include a Supplemental Note, two figures, and
one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ajhg.2017.06.002. Detailed experimental
methods are available upon request.Conflicts of Interest
M.T.C., A.B., G.D., J.J., and R.P. are employees of GeneDx.Acknowledgments
We are exceptionally grateful to the individuals and families who
participated in this study; colleagues who contributed samples and
clinical information, including Dr. John Tolmie; and Harriet Saun-
ders for technical assistance. This work was supported by institu-
tional funds from the Children’s Hospital of Philadelphia Research
Institute to C.M.S. andM.A.D. and from CureKids New Zealand to
S.P.R. The authors would like to thank the Exome Aggregation
Consortium and the groups that provided exome variant data
for comparison. We acknowledge the Deciphering Developmental
Disorders study, which presents independent research commis-
sioned by the Health Innovation Challenge Fund (grant HICF-
1009-003), a parallel funding partnership among the Wellcome
Trust, Department of Health, and Wellcome Trust Sanger Institute
(grant WT098051). The views expressed in this publication are
those of the authors and not necessarily those of the Wellcome
Trust or the Department of Health. The research team acknowl-
edges the support of the National Institute for Health Research
through the Comprehensive Clinical Research Network.
Received: January 24, 2017
Accepted: May 30, 2017
Published: July 6, 2017Web Resources
BLASTP, https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE¼Proteins
Combined Annotation Dependent Depletion (CADD), http://
cadd.gs.washington.edu/home
DECIPHER, https://decipher.sanger.ac.uk
Elements of Morphology: Human Malformation Terminology,
https://elementsofmorphology.nih.gov/146 The American Journal of Human Genetics 101, 139–148, July 6, 2Exome Aggregation Consortium (ExAC) Browser, http://exac.
broadinstitute.org
GenBank, https://www.ncbi.nlm.nih.gov/genbank/
GeneMatcher, https://genematcher.org/
Human Phenotype Ontology Browser, http://www.human-
phenotype-ontology.org
Mutation Taster, http://www.mutationtaster.org/
OMIM, http://www.omim.org/
PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
PROVEAN, http://provean.jcvi.org/index.php
RCSB Protein Data Bank, http://www.rcsb.org/pdb/home/home.do
Residual Variation Intolerance Score (RVIS), http://genic-
intolerance.org
SIFT, http://sift.jcvi.org
SubRVIS, http://www.subrvis.org
UniProtKB, http://www.uniprot.org/help/uniprotkbReferences
1. Farrell, C.M., O’Leary, N.A., Harte, R.A., Loveland, J.E., Wilm-
ing, L.G., Wallin, C., Diekhans, M., Barrell, D., Searle, S.M.,
Aken, B., et al. (2014). Current status and new features of
the Consensus Coding Sequence database. Nucleic Acids Res.
42, D865–D872.
2. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks,
E., Fennell, T.,O’Donnell-Luria,A.H.,Ware, J.S.,Hill, A.J., Cum-
mings, B.B., et al.; Exome Aggregation Consortium (2016).
Analysis ofprotein-codinggeneticvariation in60,706humans.
Nature 536, 285–291.
3. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A.
(2015). GeneMatcher: a matching tool for connecting investi-
gators with an interest in the same gene. Hum. Mutat. 36,
928–930.
4. Buske, O.J., Girdea, M., Dumitriu, S., Gallinger, B., Hartley, T.,
Trang, H., Misyura, A., Friedman, T., Beaulieu, C., Bone, W.P.,
et al. (2015). PhenomeCentral: a portal for phenotypic and
genotypic matchmaking of patients with rare genetic diseases.
Hum. Mutat. 36, 931–940.
5. Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M.,
Rajan, D., VanVooren, S., Moreau, Y., Pettett, R.M., and Carter,
N.P. (2009). DECIPHER: Database of Chromosomal Imbalance
and Phenotype in Humans Using Ensembl Resources. Am. J.
Hum. Genet. 84, 524–533.
6. Philippakis,A.A.,Azzariti,D.R.,Beltran,S.,Brookes,A.J., Brown-
stein, C.A., Brudno, M., Brunner, H.G., Buske, O.J., Carey, K.,
Doll, C., et al. (2015). The Matchmaker Exchange: a platform
for rare disease gene discovery. Hum. Mutat. 36, 915–921.
7. Shaffer, L.G., Theisen, A., Bejjani, B.A., Ballif, B.C., Aylsworth,
A.S., Lim, C., McDonald, M., Ellison, J.W., Kostiner, D., Saitta,
S., and Shaikh, T. (2007). The discovery of microdeletion syn-
dromes in the post-genomic era: review of the methodology
and characterization of a new 1q41q42 microdeletion syn-
drome. Genet. Med. 9, 607–616.
8. Filges, I., Ro¨thlisberger, B., Boesch, N., Weber, P., Wenzel, F.,
Huber, A.R., Heinimann, K., and Miny, P. (2010). Interstitial
deletion 1q42 in a patient with agenesis of corpus callosum:
Phenotype-genotype comparison to the 1q41q42 microdele-
tion suggests a contiguous 1q4 syndrome. Am. J. Med. Genet.
A. 152A, 987–993.
9. Kantarci, S., Ackerman, K.G., Russell, M.K., Longoni, M., Soug-
nez, C., Noonan, K.M., Hatchwell, E., Zhang, X., Pieretti017
Vanmarcke, R., Anyane-Yeboa, K., et al. (2010). Characteriza-
tion of the chromosome 1q41q42.12 region, and the candi-
date gene DISP1, in patients with CDH. Am. J. Med. Genet.
A. 152A, 2493–2504.
10. Mazzeu, J.F., Krepischi-Santos, A.C., Rosenberg, C., Szuhai,
K., Knijnenburg, J., Weiss, J.M., Kerkis, I., Mustacchi, Z.,
Colin, G., Mombach, R., et al. (2007). Chromosome abnor-
malities in two patients with features of autosomal domi-
nant Robinow syndrome. Am. J. Med. Genet. A. 143A,
1790–1795.
11. Rice, G.M., Qi, Z., Selzer, R., Richmond, T., Thompson, K.,
Pauli, R.M., and Yu, J. (2006). Microdissection-based high-
resolution genomic array analysis of two patients with cytoge-
netically identical interstitial deletions of chromosome 1q but
distinct clinical phenotypes. Am. J. Med. Genet. A. 140, 1637–
1643.
12. Rosenfeld, J.A., Lacassie, Y., El-Khechen, D., Escobar, L.F., Re-
ggin, J., Heuer, C., Chen, E., Jenkins, L.S., Collins, A.T., Zinner,
S., et al. (2011). New cases and refinement of the critical region
in the 1q41q42 microdeletion syndrome. Eur. J. Med. Genet.
54, 42–49.
13. Slavotinek, A.M., Moshrefi, A., Lopez Jiminez, N., Chao, R.,
Mendell, A., Shaw, G.M., Pennacchio, L.A., and Bates, M.D.
(2009). Sequence variants in the HLX gene at chromosome
1q41-1q42 in patients with diaphragmatic hernia. Clin.
Genet. 75, 429–439.
14. Wat, M.J., Veenma, D., Hogue, J., Holder, A.M., Yu, Z.,
Wat, J.J., Hanchard, N., Shchelochkov, O.A., Fernandes,
C.J., Johnson, A., et al. (2011). Genomic alterations that
contribute to the development of isolated and non-iso-
lated congenital diaphragmatic hernia. J. Med. Genet. 48,
299–307.
15. Au, P.Y., Argiropoulos, B., Parboosingh, J.S., and Micheil In-
nes, A. (2014). Refinement of the critical region of 1q41q42
microdeletion syndrome identifies FBXO28 as a candidate
causative gene for intellectual disability and seizures. Am. J.
Med. Genet. A. 164A, 441–448.
16. Cassina, M., Rigon, C., Casarin, A., Vicenzi, V., Salviati, L., and
Clementi, M. (2015). FBXO28 is a critical gene of the 1q41q42
microdeletion syndrome. Am. J. Med. Genet. A. 167, 1418–
1420.
17. Chang, Y.F., Imam, J.S., and Wilkinson, M.F. (2007). The
nonsense-mediated decay RNA surveillance pathway. Annu.
Rev. Biochem. 76, 51–74.
18. Kervestin, S., and Jacobson, A. (2012). NMD: a multifaceted
response to premature translational termination. Nat. Rev.
Mol. Cell Biol. 13, 700–712.
19. Zhu, Y., Wang, Y., Xia, C., Li, D., Li, Y., Zeng,W., Yuan,W., Liu,
H., Zhu, C., Wu, X., and Liu, M. (2004). WDR26: a novel
Gbeta-like protein, suppresses MAPK signaling pathway.
J. Cell. Biochem. 93, 579–587.
20. Sun, Z., Tang, X., Lin, F., and Chen, S. (2011). The WD40
repeat protein WDR26 binds Gbg and promotes Gbg-depen-
dent signal transduction and leukocyte migration. J. Biol.
Chem. 286, 43902–43912.
21. Petrovski, S., Gussow, A.B., Wang, Q., Halvorsen, M., Han,
Y., Weir, W.H., Allen, A.S., and Goldstein, D.B. (2015). The
Intolerance of Regulatory Sequence to Genetic Variation
Predicts Gene Dosage Sensitivity. PLoS Genet. 11,
e1005492.
22. Gussow, A.B., Petrovski, S., Wang, Q., Allen, A.S., and Gold-
stein, D.B. (2016). The intolerance to functional genetic vari-The Amation of protein domains predicts the localization of patho-
genic mutations within genes. Genome Biol. 17, 9.
23. Dias, J., Van Nguyen, N., Georgiev, P., Gaub, A., Brettsch-
neider, J., Cusack, S., Kadlec, J., and Akhtar, A. (2014). Struc-
tural analysis of the KANSL1/WDR5/KANSL2 complex reveals
that WDR5 is required for efficient assembly and chromatin
targeting of the NSL complex. Genes Dev. 28, 929–942.
24. Goto, T., Matsuzawa, J., Iemura, S., Natsume, T., and Shibuya,
H. (2016). WDR26 is a new partner of Axin1 in the canonical
Wnt signaling pathway. FEBS Lett. 590, 1291–1303.
25. Zhao, J., Liu, Y., Wei, X., Yuan, C., Yuan, X., and Xiao, X.
(2009). A novel WD-40 repeat protein WDR26 suppresses
H2O2-induced cell death in neural cells. Neurosci. Lett. 460,
66–71.
26. Wei, X., Song, L., Jiang, L., Wang, G., Luo, X., Zhang, B., and
Xiao, X. (2010). Overexpression of MIP2, a novel WD-repeat
protein, promotes proliferation of H9c2 cells. Biochem. Bio-
phys. Res. Commun. 393, 860–863.
27. Stirnimann, C.U., Petsalaki, E., Russell, R.B., and Mu¨ller, C.W.
(2010). WD40 proteins propel cellular networks. Trends Bio-
chem. Sci. 35, 565–574.
28. Feng, Y., Zhang, C., Luo, Q., Wei, X., Jiang, B., Zhu, H., Zhang,
L., Jiang, L., Liu, M., and Xiao, X. (2012). A novel WD-
repeat protein, WDR26, inhibits apoptosis of cardiomyocytes
induced by oxidative stress. Free Radic. Res. 46, 777–784.
29. Sun, Z., Smrcka, A.V., and Chen, S. (2013). WDR26 functions
as a scaffolding protein to promote Gbg-mediated phospholi-
pase C b2 (PLCb2) activation in leukocytes. J. Biol. Chem. 288,
16715–16725.
30. Ye, Y., Tang, X., Sun, Z., and Chen, S. (2016). Upregulated
WDR26 serves as a scaffold to coordinate PI3K/ AKT
pathway-driven breast cancer cell growth, migration, and
invasion. Oncotarget 7, 17854–17869.
31. Zweier, C., de Jong, E.K., Zweier, M., Orrico, A., Ousager, L.B.,
Collins, A.L., Bijlsma, E.K., Oortveld, M.A., Ekici, A.B., Reis, A.,
et al. (2009). CNTNAP2 and NRXN1 are mutated in auto-
somal-recessive Pitt-Hopkins-like mental retardation and
determine the level of a common synaptic protein in
Drosophila. Am. J. Hum. Genet. 85, 655–666.
32. Rohatgi, S., Clark, D., Kline, A.D., Jackson, L.G., Pie, J., Siu,
V., Ramos, F.J., Krantz, I.D., and Deardorff, M.A. (2010).
Facial diagnosis of mild and variant CdLS: Insights from
a dysmorphologist survey. Am. J. Med. Genet. A. 152A,
1641–1653.
33. Kaiser, F.J., Ansari, M., Braunholz, D., Concepcio´n Gil-Rodrı´-
guez, M., Decroos, C., Wilde, J.J., Fincher, C.T., Kaur, M.,
Bando, M., Amor, D.J., et al.; Care4Rare Canada Consortium;
and University of Washington Center for Mendelian Geno-
mics (2014). Loss-of-function HDAC8 mutations cause a
phenotypic spectrum of Cornelia de Lange syndrome-like fea-
tures, ocular hypertelorism, large fontanelle and X-linked
inheritance. Hum. Mol. Genet. 23, 2888–2900.
34. Deardorff, M.A., Wilde, J.J., Albrecht, M., Dickinson, E., Tenn-
stedt, S., Braunholz, D., Mo¨nnich, M., Yan, Y., Xu, W., Gil-Ro-
drı´guez, M.C., et al. (2012). RAD21 mutations cause a human
cohesinopathy. Am. J. Hum. Genet. 90, 1014–1027.
35. Nikkel, S.M., Dauber, A., de Munnik, S., Connolly, M., Hood,
R.L., Caluseriu, O., Hurst, J., Kini, U., Nowaczyk, M.J., Afenjar,
A., et al.; FORGE Canada Consortium (2013). The phenotype
of Floating-Harbor syndrome: clinical characterization of 52
individuals with mutations in exon 34 of SRCAP. Orphanet
J. Rare Dis. 8, 63.erican Journal of Human Genetics 101, 139–148, July 6, 2017 147
36. Ausio´, J., Levin, D.B., De Amorim, G.V., Bakker, S., and Ma-
cleod, P.M. (2003). Syndromes of disordered chromatin re-
modeling. Clin. Genet. 64, 83–95.
37. Schrier, S.A., Bodurtha, J.N., Burton, B., Chudley, A.E., Chiong,
M.A., D’avanzo, M.G., Lynch, S.A., Musio, A., Nyazov, D.M.,
Sanchez-Lara, P.A., et al. (2012). The Coffin-Siris syndrome: a
proposed diagnostic approach and assessment of 15 overlap-
ping cases. Am. J. Med. Genet. A. 158A, 1865–1876.148 The American Journal of Human Genetics 101, 139–148, July 6, 238. Yuan, B., Pehlivan, D., Karaca, E., Patel, N., Charng, W.L.,
Gambin, T., Gonzaga-Jauregui, C., Sutton, V.R., Yesil, G., Boz-
dogan, S.T., et al. (2015). Global transcriptional disturbances
underlie Cornelia de Lange syndrome and related phenotypes.
J. Clin. Invest. 125, 636–651.
39. Izumi, K. (2016). Disorders of Transcriptional Regulation: An
Emerging Category of Multiple Malformation Syndromes.
Mol. Syndromol. 7, 262–273.017
